Developing ideal therapies for
Ocular diseases, such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, are debilitating and can deprive people of their vision.
Current treatments have limited durability and are unable to correct the underlying disease pathology resulting in an untenable treatment burden and failure to fully restore vision.
Our business is to develop safer, more efficacious, and longer-lasting therapeutics for ocular diseases.
Aptitude is developing ideal treatments for vision-threatening diseases. We develop next-generation synthetic biomolecules that are capable of potently suppressing multiple pathological processes simultaneously to yield maximal efficacy.
Our drug candidates possess exceptional stability, solubility, and half-life to yield extended duration to minimize treatment burden. Most importantly, our drug modality is non-immunogenic, predictable and proven safe.
Together, these capabilities allow us to overcome the unique challenges of ocular therapies to deliver novel solutions to restore and maintain vision.